KNSA · Kiniksa Pharmaceuticals International, plc
$76.75
-1.08 (-1.39%)
At close · Aug 14
Market Cap
$11.98B
Shares
156.05M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Eben Tessari | Chief Strategy Officer | Resigned | 2026-05-01 |
| Eben Tessari | Chief Strategy Officer | Appointed | 2026-01-14 |
| Ross Moat | Chief Operating Officer and principal operating officer | Appointed | 2026-01-14 |
| M. Cantey Boyd | member of the Board | Appointed | 2024-10-07 |
Key facts
CIK
1730430
CUSIP
G52694109
13F (30d)
257 filings
254 filers
Visit website
Investor relations